22
Cancer Clinical Trials Aimed at Decreasing Toxicity

1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

Embed Size (px)

Citation preview

Page 1: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

Cancer Clinical Trials Aimed at Decreasing

Toxicity

Page 2: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

2) iron out how to efficiently move the most promising agents into appropriate clinical trials

3) develop a summary "position paper" to be published

Page 3: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients
Page 4: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

• Minimize DELAY and CONFUSION

Page 5: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients
Page 6: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

• Quality of life (mid 1980’s)

• Fatigue (2000)

• Curcumin  (2006)

Page 7: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

QOL and cancer in title 1980 =  2 = .05% of articles with cancer in title (cancer alone = 3966)QOL and cancer 2008 =  355 = 1.2% of articles with cancer in title (cancer alone = 29940)

Page 8: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients
Page 9: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients
Page 10: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients
Page 11: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

• June 30, 2006  IND submitted• August 4, 2006 IND approved• August 31, 2006 “complete clinical

hold”

• July 25, 2007 “proceed”• July 26, 2007 “hold”• August 16, 2007 “approved”

Page 12: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

Involved :• 9 FDA staff• 4 FDA divisions• 1 FDA Ombudsman• 1FDA Chief• 1 US Congresswoman• 1 US Senator• 8 University of Rochester people

And 57 separate contacts over the 412 days

Page 13: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

What is a CCOP Research Base?

An NCI-designated Cancer Center or Cooperative Group

Funded by a Peer- Reviewed Cooperative Agreement

Develop and Conduct Cancer Prevention and Control Clinical Trials

Supports Development of Cancer Prevention Science

Page 14: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

CCOP Research Bases: Cooperative Groups

▪ Children’s Oncology Group▪ Cancer and Leukemia Group B▪ Eastern Cooperative Oncology Group▪ North Central Cancer Treatment Group▪ Radiation Therapy Oncology Group▪ Southwest Oncology Group▪ National Surgical Adjuvant Breast &

Bowel Project▪ Gynecologic Oncology Group

Page 15: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

CCOP Research Bases: Cancer Centers

H. Lee Moffitt Cancer Center M.D. Anderson Cancer Center University of Rochester Cancer Center

Wake Forest University Cancer Center

Page 16: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

Central Illinois CCOP Gulf Coast MBCCOP North Shore University Hospital CCOPColumbia River CCOP Hawaii MBCCOP Northwest CCOP

Columbus CCOP Hematology-Oncology of CNY CCOPSoutheast Cancer Control Consortium

Dayton Clinical Oncology Program Kalamazoo CCOPUniversity of Illinois at Chicago MBCCOP

Evanston CCOP Kansas City CCOP Upstate Carolina CCOP

Grand Rapids CCOPMarshfield Clinic Research Foundation CCOP

Virginia Mason Research Center CCOP

Greenville CCOP Metro-Minnesota CCOP Wichita CCOPNevada Cancer Research Foundation CCOP

CCOPs

URCC

UNIVERSITY OF ROCHESTER CANCER CENTERCOMMUNITY CLINICAL ONCOLOGY RESEARCH BASEMAP OF AFFILIATES (2009)

Page 17: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

0

2

4

6

8

10

2000 2001 2002 2003 2004 2005 2006 2007 2008Cancer Control Accruals(CCOPs and MBCCOPs)

Tho

usan

ds

Page 18: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients
Page 19: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

• What is appropriate FDA review expertise for this research? 

• Where is it found administratively? 

• How can mutually beneficial collaborative  relationships be promoted?

• Is there a way to have this all be more timely?

Page 20: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

Gary Morrow, PhD, MS URCC CCOP Research Base 20

Page 21: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

CCOPs & [MB-CCOPs]

Accrual to Protocols

Data Management

Quality Control

Research Bases

(Groups/Centers)

Develop Protocols

Data Management and Analysis

Quality Assurance

Members and Affiliates

Accrual to Prevention and Control Protocols

Page 22: 1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients

March 2007

(50)(13)

(395)